Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel medical compound being capable of synergetically suppressing growth of tumors

A composition and drug technology, applied in the field of new pharmaceutical compositions capable of synergistically inhibiting tumor growth

Inactive Publication Date: 2009-10-14
MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

According to the present invention, there is no relevant report at home and abroad on the study of improving the therapeutic effect of tumors by utilizing the synergistic effect of the novel pharmaceutical composition TMZ / LDM

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel medical compound being capable of synergetically suppressing growth of tumors
  • Novel medical compound being capable of synergetically suppressing growth of tumors
  • Novel medical compound being capable of synergetically suppressing growth of tumors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] The synergistic inhibitory effect of LDM and TMZ on the proliferation of rat glioma C6 cells and human glioma U87 cells

[0055] The cytotoxicity of the two drugs was detected by the MTT method, and the operation was as follows:

[0056] 1). Take the cells in the logarithmic growth phase, digest and count them at 1×10 3 cells / well (C6 cells), 1.5×10 3 pcs / well (U87 cells) or 2×10 3 Cells were seeded in 96-well cell culture plates at a density of one per well (rCMEC cells), with at least 3 parallel wells in each group.

[0057] 2). After 24 hours, different concentrations of drugs were added for treatment.

[0058] 3). After 72 hours, add 5 mg / ml MTT solution prepared with PBS buffer, add 20 μl to each well, and incubate at 37° C. for 4 hours.

[0059] 4). Aspirate the supernatant, add 150 μl DMSO, and shake for 10 minutes to fully dissolve the crystals.

[0060] 5). Measure the absorbance (A) of each well at 570 nm with a microplate reader.

[0061] 6). The calcu...

Embodiment 2

[0064] The synergistic effect of the combined application of LDM and TMZ on the apoptosis of rat glioma C6 cells and human glioma U87 cells

[0065] Annexin V-FITC / PI (fluorescein isothiocyanate-labeled annexin V / propidium iodide) method was used to detect the effect of drug combination on cell apoptosis. The operation is as follows:

[0066] 1) Inoculate cells: 10×10 4 pcs / well (C6 cells), 15×10 4 pcs / well (U87 cells) or 20×10 4 Cells were seeded at a density of 1 / well (rCMEC cells) in 6-well cell culture plates.

[0067] 2) Cultivate in an incubator with 5% CO2 concentration at 37°C for 24 hours.

[0068] 3) Drug-treated cells, rat brain microvascular endothelial cells and rat glioma C6 cells were treated with LDM 0.1nmol / L and TMZ 300μmol / L or a combination of the two; human glioma U87 cells were treated with LDM 0.05 nmol / L and TMZ 210μmol / L or a combination of both.

[0069] 4) Continue culturing for 72 hours in an incubator with 5% CO2 concentration at 37°C.

[0...

Embodiment 3

[0077] The synergistic inhibitory effect of LDM and TMZ on the tubule formation ability of rat brain microvascular endothelial cells

[0078] Tube formation (Tube formation) assay was used to detect the effect of drug combination on angiogenesis. The operation is as follows:

[0079] 1) Pre-cool the pipette tip and the 96-well culture plate.

[0080] 2) Operate on an ice platform, add 50 μl of Matrigel gel, and place at 37° C. for 30 minutes to pre-solidify.

[0081] 3) Collect 2-3 generations of cells in good growth condition, digest with trypsin, centrifuge and count.

[0082] 4) Take 2×10 diluted 180 μl culture solution (containing 10% common fetal bovine serum) 4 cells / well.

[0083] 5) Treatment with different drug combinations (LDM: 0.1 nmol / L, TMZ: 200 μmol / L, and LDM 0.1 nmol / L+TMZ 200 μmol / L).

[0084] 6) Put it in the incubator for 16 hours until the lumen-like structure is formed.

[0085] 7) Take a picture under an inverted microscope at a magnification of ×...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a novel synergetic medical compound being capable of suppressing growth of tumors, which consists of an enediyne drug and an alkylated chemotherapeutic drug, i.e. lidamycin and temodar; relevant researches prove that the medical compound can synergetically resist the multiplication of the tumor cells, induce apoptosis and suppress angiogenesis; in vivo test has an obvious curative effect on nude mice transplanted tumor of the human neuroglioma U87 cells. The medical compound has an enhanced function of suppressing the growth of tumors and angiogenesis in tumor tissues, thus displaying a synergetic tumor suppressing effect and having good application prospect.

Description

Technical field: [0001] The invention relates to the application of a novel pharmaceutical composition capable of synergistically enhancing and inhibiting tumor growth. Background technique: [0002] Tumor is a frequently-occurring and common disease that threatens human health. Glioma is the most common primary brain tumor in adults and is very harmful. Although surgery, radiotherapy and chemotherapy have made great progress, in fact, only for nervous system tumors, including glioma patients, the survival rate and quality of life have not changed significantly in the past ten years. At present, the main chemotherapy drugs used to treat glioma are nitrosoureas or alkylating agents, but gliomas also have drug resistance to these drugs [N Engl JMed (New England Medicine), 2005, 352(10): 987-996], the clinical treatment of glioma is mostly a combination of radiotherapy and chemotherapy, and the main chemotherapeutic drugs are single or single or mainly nitrosoureas or alkylati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/16A61P35/00A61K31/4188
Inventor 李兴起甄永苏张胜华欧阳志钢商悦
Owner MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com